

Title (en)  
PROPHYLACTIC DIETARY SUPPLEMENT BASED ON MILK

Title (de)  
VORBEUGENDER DIETAETISCHER LEBENSMITTELZUSATZ AUF BASIS VON MILCH

Title (fr)  
COMPLEMENTS ALIMENTAIRES PROPHYLACTIQUES A BASE DE LAIT

Publication  
**EP 1196047 A4 20041222 (EN)**

Application  
**EP 00942589 A 20000629**

Priority  
• NZ 0000116 W 20000629  
• NZ 33650599 A 19990629  
• NZ 50405700 A 20000418

Abstract (en)  
[origin: WO0100047A1] Milk is commonly and extensively consumed in many societies where the risk and incidence of diabetes, vascular disease (CHD, CVA, PVD) and some cancers are also high. Death is a frequent sequel of systemic vascular wall damage, resulting from exposure to high sugar levels in diabetes and also from high plasma homocyst(e)ine (tHcy) levels that affect much of the population and comprise a major risk factor for vascular disease. Diabetes is similarly widespread. Given (1) widespread and regular consumption of milk, (2) the possibility to control tHcy by treating the underlying folate (and other vitamin) insufficiency, (3) the opportunity to simply include control of neural tube defects and (4) the presumed causal link between diabetes and type A1 with type B casein consumption, the invention offers remediation by supplying a population with a modified milk or milk product including (1) fortification using cobalamin, pyridoxine, folic acid, and betaine, with (2) a substantially type A2 casein fraction only. In addition, exploitation of the immunological properties of beta-casomorphin 9 (a peptide digest fraction of A2 beta-casein) may assist in control of diabetes. Practical and convenient fortified diets include treated, selected milks and food products including derivatives of milk, also selected milks together with treated cereals.

IPC 1-7  
**A23L 1/305; A23C 9/158; A23C 9/20; A23L 1/302**

IPC 8 full level  
**A23L 1/30** (2006.01); **A23C 9/152** (2006.01); **A23C 9/158** (2006.01); **A23L 1/305** (2006.01); **A23L 33/15** (2016.01); **A61K 31/205** (2006.01); **A61K 31/4415** (2006.01); **A61K 31/519** (2006.01); **A61K 31/714** (2006.01); **A61K 35/20** (2006.01); **A61P 3/02** (2006.01); **A61P 3/10** (2006.01); **A61P 7/00** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 11/06** (2006.01); **A61P 15/00** (2006.01); **A61P 25/28** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)  
**A23C 9/152** (2013.01); **A23C 9/158** (2013.01); **A23L 33/15** (2016.07); **A23L 33/19** (2016.07); **A61P 3/02** (2017.12); **A61P 3/10** (2017.12); **A61P 7/00** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 11/06** (2017.12); **A61P 15/00** (2017.12); **A61P 25/28** (2017.12); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **A61P 43/00** (2017.12); **A23V 2002/00** (2013.01)

Citation (search report)  
• [XA] WO 9636239 A1 19961121 - MCLACHLAN CORRAN NORMAN STUART [NZ]  
• [A] EP 0347864 A2 19891227 - STRYDOM ANDRIES JOHANNES CORNE  
• [A] US 5668173 A 19970916 - GARROW TIMOTHY A [US]  
• [A] R. ELLIOTT: "Type I diabetes mellitus and cow milk: casein variant consumption", DIABETOLOGIA, vol. 42, 1999, pages 292 - 296, XP002302666  
• See references of WO 0100047A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0100047 A1 20010104**; AU 5719200 A 20010131; AU 771754 B2 20040401; CN 1159984 C 20040804; CN 1368853 A 20020911; EP 1196047 A1 20020417; EP 1196047 A4 20041222; JP 2003503038 A 20030128

DOCDB simple family (application)  
**NZ 0000116 W 20000629**; AU 5719200 A 20000629; CN 00809817 A 20000629; EP 00942589 A 20000629; JP 2001505772 A 20000629